Endocyte (Endocyte) Intrinsic Value: Projected FCF : $0.00 (As of Apr. 27, 2024)

Endocyte Intrinsic Value: Projected FCF Chart

Endocyte Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
Intrinsic Value: Projected FCF		Get a 7-Day Free Trial					-	2.43	-0.39	-1.57	-2.46

Endocyte Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Intrinsic Value: Projected FCF	Get a 7-Day Free Trial															-2.81	-2.46	-0.97	-3.52	-1.59

Competitive Comparison of Endocyte's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Endocyte's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endocyte's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endocyte's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Endocyte's Price-to-Projected-FCF falls into.

Endocyte Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)

Add all the Free Cash Flow together and divide 6 will get Endocyte's Free Cash Flow(6 year avg) = $-40.64.

Endocyte's Intrinsic Value: Projected FCF for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endocyte  (NAS:ECYT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Endocyte's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endocyte Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Endocyte's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Endocyte (Endocyte) Business Description